002275 Guilin Sanjin Pharmaceutical
- 13.41
- -0.16-1.18%
Guilin Sanjin Pharmaceutical News
Guilin Sanjin Pharmaceutical (002275.SZ): The actual controller and chairman of the company has completed the shareholding plan, with a cumulative shareholding of 0.383 million shares.
Guilin SanJin (002275.SZ) announced on September 2nd that the company disclosed the "Announcement on the Shareholding Plan of the Actual Controller, Chairman, and CEO of the Company" on March 2, 2024. Mr. Zou Xun, the actual controller, chairman, and CEO of the company, plans to use his own funds to increase his shareholding in the company through centralized bidding or bulk trading on the Shenzhen Stock Exchange within six months starting from March 2, 2024. The amount of shareholding increase shall not be less than 5 million RMB. From March 2, 2024 to September 1, 2024, Mr. Zou Xun has cumulatively increased his shareholding through centralized bidding on the Shenzhen Stock Exchange.
Guilin Sanjin (002275): Q2 performance exceeds expectations, core product demand is supported.
Event: On August 28, guilin sanjin pharmaceutical released the "2024 semi-annual report". In 2024H1, the company achieved a revenue of 1.068 billion yuan, a decrease of 10.5% year-on-year; achieved a net income attributable to the parent company of 0.301 billion yuan.
Guilin Sanjin Pharmaceuticals (002275): Significant improvement in Q2 performance, solidifying the global strategy for sustained and stable growth.
Performance meets expectations, Q2 performance improved significantly on a quarter-on-quarter basis. The company released the 2024 interim report: Revenue for H1 2024 was 1.068 billion yuan (-10.53%), and net income attributable to the parent company was 0.301 billion yuan (-20.70%).
Guilin Sanjin: Semi-Annual Report 2024
Guilin Sanjin: 2024 Semi-Annual Report Summary
Express News | Guilin Sanjin Pharmaceutical: Net income in the first half of the year was 0.301 billion yuan, a year-on-year decrease of 20.70%.
Guilin Sanjin Pharmaceutical (002275.SZ) announced its performance for the first half of the year, with a net income of 0.301 billion yuan, a decrease of 20.70%.
Guilin Sanjin (002275.SZ) released the 2024 interim report, during the reporting period, the company achieved revenue...
Guilin Sanjin Pharmaceutical (002275.SZ): net income of 0.301 billion yuan in the first half of the year, a year-on-year decrease of 20.70%.
Guilin Sanjin (002275.SZ) released its interim report for the first half of 2024, with operating revenue of 1.068 billion yuan, a decrease of 10.53% year-on-year. The net income attributable to shareholders of the listed company was 0.301 billion yuan, a decrease of 20.70% year-on-year. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.274 billion yuan, a decrease of 25.21% year-on-year. The basic earnings per share was 0.51 yuan.
Express News | Guilin Sanjin Pharmaceutical: Controlled subsidiary BC011 monoclonal antibody injection obtained clinical trial approval.
Guilin Sanjin Pharmaceutical (002275.SZ): As of July 19th, 2024, the total number of shareholders is 18640.
Guilin Sanjin Pharmaceutical (002275.SZ) stated on the investor interaction platform on July 24th that as of July 19, 2024, the total number of shareholders was 18,640.
Guilin Sanjin Pharmaceutical (002275.SZ): The proportion of Sanjin Pills in the hospital is slightly higher than that of Xigua Frost.
Guilin Sanjin (002275.SZ) recently stated during a reception for institutional investors that the company mainly produces dual-use drugs, with varying proportions for each type. Overall, OTC drugs are the main focus, while prescription drugs are a secondary focus, accounting for approximately 80% and 20%, respectively. For the Watermelon Frost series, the proportion of OTC drugs is always higher than prescription drugs, approximately 80% to 20%, while the hospital usage of Sanjin Tablets is slightly higher than Watermelon Frost.
Express News | Guilin Sanjin Pharmaceutical: frontline products such as the Watermelon Frost series are currently undergoing second-stage product development.
Express News | Guilin Sanjin Pharmaceutical: Sales revenue of first-line products such as Xigua Frost series accounts for nearly 80% of the total.
Guilin Sanjin Pharmaceutical (002275.SZ): From the perspective of the whole year, the company strives to complete this year's tasks according to the budget.
Guilin Sanjin (002275.SZ) stated during an investor relations event on June 20th that the company's first quarter performance declined compared to the same period last year mainly due to the impact of a public health event during the same period last year, which resulted in a significant increase in sales for the current period as a result of normal market supply. At the same time, excluding the impact of special circumstances from the first quarter of last year, the sales volume for the first quarter of 24, 22, 21 and previous years is also at a high level compared to the same period. The company also announced its budget for this year and aims to accomplish this year's tasks according to the budget for the whole year.
Guilin Sanjin Pharmaceutical (002275.SZ): The actual controller Zou Xun has passed the halfway mark of the shareholding period and has accumulated 148,300 shares.
Guilin Sanjin Pharmaceutical (002275.SZ) announced on June 3rd that as of June 1st, 2024, more than half of the shareholding plan had passed. Mr. Zou Xun, the actual controller, chairman and CEO of the company, has accumulated 148,300 shares of the company's stock through centralized bidding on the Shenzhen Stock Exchange, accounting for 0.03% of the company's existing total share capital. The total amount of shareholding is 2.0472 million yuan.
Express News | Guilin Sanjin: The company now accounts for a large share of OTC. The next step is to increase sales on the hospital side
Guilin Sanjin (002275.SZ): 2023 equity distribution 10 distribution 3 yuan share registration date May 28
Gelonghui, May 20 | Guilin Sanjin (002275.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 3.000000 in cash (tax included) to all shareholders for every 10 shares based on the company's current total share capital excluding 587,568,600 shares after excluding 0 shares that have already been repurchased. The share registration date for this equity distribution is May 28, 2024, and the ex-dividend date is May 29, 2024.
Express News | Guilin Sanjin: Currently, the company is not involved in fields related to synthetic biology
Guilin Sanjin (002275): Q1 performance returns to normal, high dividend policy is expected to continue
Incident: On April 25, Guilin Sanjin released the “2023 Annual Report” and “2024 First Quarter Report”. In 2023, the company achieved revenue of 2.112 billion yuan, an increase of 10.8% over the previous year; in fact
Guilin Sanjin (002275): Performance is in line with expectations, and the two wings move forward steadily
The performance was in line with expectations. Based on high-base performance in the first quarter, the company released the 2023 annual report and the 2024 quarterly report: in 2023, the company achieved revenue of 2.112 billion yuan (+10.81%), and net profit to mother4
Analysis
Price Target
No Data
